FRONTEO and Astellas Pharma Sign Agreement on Target Molecule Discovery
AI company FRONTEO and Astellas Pharma have signed an agreement regarding target molecule discovery in drug creation. FRONTEO will provide its proprietary specialized AI, 'KIBIT,' to support Astellas Pharma's drug discovery research.
📋 Article Processing Timeline
- 📰 Published: April 16, 2026 at 16:00
- 🔍 Collected: April 16, 2026 at 16:31 (31 min after Published)
- 🤖 AI Analyzed: April 19, 2026 at 01:24 (56h 52m after Collected)
Our group provides solutions based on our proprietary specialized AI 'KIBIT' in four businesses requiring expertise in life sciences, economic security, business intelligence, and legal tech. KIBIT is a domestically produced AI that supports expert decision-making using natural language processing technology (patented in Japan, the US, and Europe) and structuring technology that maps analysis results (patented in Japan and the US).